Evidence map›Paper›PMID 32937031›Full record

ArticleFEBS open bio2020

Dissecting the transactivation domain (tAD) of the transcription factor c-Myb to assess recent models of tAD function.

Guro Naes, Jan Ove Storesund, Priyanga-Dina Udayakumar, Marit Ledsaak, Odd Stokke Gabrielsen

Abstract read
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guro NaesDepartment of Biosciences, University of Oslo, Norway.
Jan Ove StoresundDepartment of Biosciences, University of Oslo, Norway.
Priyanga-Dina UdayakumarDepartment of Biosciences, University of Oslo, Norway.
Marit LedsaakDepartment of Biosciences, University of Oslo, Norway.
Odd Stokke GabrielsenDepartment of Biosciences, University of Oslo, Norway.ORCID 0000-0002-5975-8815

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription factors use a DNA-binding domain to localize their action and a transactivation domain (tAD) to stimulate activation of the associated gene. Recent work has renewed interest in how tADs activate genes, which remains poorly understood. Key features in the new models are exposure of short linear motifs (SLMs) and liquid-liquid phase separation (LLPS). Inspired by the new models for tAD function, we decided to revisit the tAD of the haematopoietic transcription factor c-Myb by performing a mutational analysis to see how these new models fit and potentially explain the tAD behaviour of this master regulator. We know that c-Myb has an acidic tAD, which contains a well-characterized SLM in the form of a LxxLL motif. By testing 12 alanine-scanning mutants and three mutants with major reorganization of its tAD in two mammalian reporter systems, we found a pattern of effects very close to what would be expected from the SLM-exposure model, with strong effects exerted by both acidic replacements and SLM mutation. When the same mutants were tested in a yeast system, the pattern of effects was dramatically different, with the SLM mutation exerting no effect, and tAD behaviour was much less affected by small alterations, as would be expected from a LLPS model. These observations are discussed in the light of the two new tAD models, and a two-step hypothesis for transactivation, combining both models, is proposed.

Indexed as

Models, BiologicalTranscriptional ActivationAmino Acid SequenceAnimalsChromatinDNA Mutational AnalysisHEK293 CellsHumansMutant ProteinsProtein DomainsProto-Oncogene Proteins c-mybSaccharomyces cerevisiaeChromatinMutant ProteinsProto-Oncogene Proteins c-mybchromatinc-Mybtransactivation domaintranscription factoryeast

Identifiers

PMID32937031
PMCPMC7609802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.